Drug Trial Radar · NCT02774044
Efficacy and Safety of Goat Lung Surfactant for the Treatment of Respiratory Distress Syndrome in Preterm Neonates
Last checked: Nov 19, 2026Latest source record: May 17, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
900
Planned (sponsor's estimate)
Start
Jun 2016
Primary completion
Feb 2019
Study completion May 2019
Sponsor
- Lead sponsor
- Ramesh K AgarwalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Maulana Azad Medical College, New Delhi; Lady Hardinge Medical College; Chacha Nehru Bal Chikitsalya, Delhi; Post Graduate Institute of Medical Education and Research, Chandigarh; King Edward Memorial Hospital, Mumbai; Lokmanya Tilak Municipal General Hospital, Mumbai; Institute of Child health and Hospital for Children, Chennai; Jawaharlal Institute of Postgraduate Medical Education & Research; All India Institute of Medical Sciences; St Johns Medical College Hospital, Bangalore, India; King Edward Memorial Hospital, Pune; Government Medical College, Chandigarh; Wellcome Trust
- First posted
- May 17, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 26 weeks, up to 32 weeks
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate the efficacy and safety of Cadisurf (goat lung surfactant extract) as compared to Survanta (beractant) in the treatment of respiratory distress syndrome in preterm neonates (with gestation of 26 to 32 weeks).
Conditions
- Respiratory Distress Syndrome
Interventions
CadisurfDrug
Cadisurf Intratracheal suspension is a sterile, non-pyrogenic pulmonary surfactant intended for intratracheal use only. It is a natural lung extract containing phospholipids and surfactant-associated proteins. The resulting composition provides 25 mg/mL phospholipids and less than 1.0 mg/ml protein. It is suspended in 0.9% sodium chloride solution. Cadisurf contains no preservatives. Each ml of Cadisurf contains 25 mg of phospholipids. It is a creamy white suspension supplied in single-use glass vials containing 8 mL (200 mg phospholipids).
SurvantaDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- BPD free survivalTime frame: 36 weeks post menstrual age
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.